Tr1 Cells Emerge and Suppress Effector Th17 Cells in Glomerulonephritis

T regulatory type 1 (Tr1) cells, which are defined by their regulatory function, lack of Foxp3, and high expression of IL-10, CD49b, and LAG-3, are known to be able to suppress Th1 and Th17 in the intestine. Th1 and Th17 cells are also the main drivers of crescentic glomerulonephritis (GN), the most...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of immunology (1950) 2023-12, Vol.211 (11), p.1669-1679
Main Authors: Soukou-Wargalla, Shiwa, Kilian, Christoph, Velasquez, Lis N, Machicote, Andres, Letz, Philine, Tran, Huu Ban, Domanig, Saskia, Bertram, Franziska, Stumme, Friederike, Bedke, Tanja, Giannou, Anastasios, Kempski, Jan, Sabihi, Morsal, Song, Ning, Paust, Hans-Joachim, Borchers, Alina, Garcia Perez, Laura, Pelczar, Penelope, Liu, Beibei, Ergen, Can, Steglich, Babett, Muscate, Franziska, Huber, Tobias B, Panzer, Ulf, Gagliani, Nicola, Krebs, Christian F, Huber, Samuel
Format: Article
Language:English
Subjects:
Animals
Glomerulonephritis
Humans
Interleukin-10 - metabolism
Kidney - metabolism
Mice
T-Lymphocytes, Regulatory
Th1 Cells
Th17 Cells
Transcription Factors - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:T regulatory type 1 (Tr1) cells, which are defined by their regulatory function, lack of Foxp3, and high expression of IL-10, CD49b, and LAG-3, are known to be able to suppress Th1 and Th17 in the intestine. Th1 and Th17 cells are also the main drivers of crescentic glomerulonephritis (GN), the most severe form of renal autoimmune disease. However, whether Tr1 cells emerge in renal inflammation and, moreover, whether they exhibit regulatory function during GN have not been thoroughly investigated yet. To address these questions, we used a mouse model of experimental crescentic GN and double Foxp3mRFP IL-10eGFP reporter mice. We found that Foxp3neg IL-10-producing CD4+ T cells infiltrate the kidneys during GN progression. Using single-cell RNA sequencing, we could show that these cells express the core transcriptional factors characteristic of Tr1 cells. In line with this, Tr1 cells showed a strong suppressive activity ex vivo and were protective in experimental crescentic GN in vivo. Finally, we could also identify Tr1 cells in the kidneys of patients with antineutrophil cytoplasmic autoantibody-associated GN and define their transcriptional profile. Tr1 cells are currently used in several immune-mediated inflammatory diseases, such as T-cell therapy. Thus, our study provides proof of concept for Tr1 cell-based therapies in experimental GN.
ISSN:0022-1767
1550-6606
DOI:10.4049/jimmunol.2300305